Iyuzeh is a drug owned by Thea Pharma Inc. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 08, 2031. Details of Iyuzeh's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8637054 | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives |
Jul, 2031
(5 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Iyuzeh's patents.
Latest Legal Activities on Iyuzeh's Patents
Given below is the list of recent legal activities going on the following patents of Iyuzeh.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Jul, 2025 | US8637054 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Jul, 2021 | US8637054 |
| Patent Issue Date Used in PTA Calculation | 28 Jan, 2014 | US8637054 |
| Recordation of Patent Grant Mailed | 28 Jan, 2014 | US8637054 |
| Email Notification | 09 Jan, 2014 | US8637054 |
| Issue Notification Mailed | 08 Jan, 2014 | US8637054 |
| Application Is Considered Ready for Issue | 23 Dec, 2013 | US8637054 |
| Dispatch to FDC | 23 Dec, 2013 | US8637054 |
| Issue Fee Payment Verified | 17 Dec, 2013 | US8637054 |
| Issue Fee Payment Received | 17 Dec, 2013 | US8637054 |
US patents provide insights into the exclusivity only within the United States, but
Iyuzeh is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Iyuzeh's family patents as well as insights into
ongoing legal events
on those patents.
Iyuzeh's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Iyuzeh's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 08, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Iyuzeh Generic API suppliers:
Latanoprost is the generic name for the brand Iyuzeh. 12 different companies have already filed for the generic of Iyuzeh, with Amring Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Iyuzeh's generic
Alternative Brands for Iyuzeh
Iyuzeh which is used for reducing intraocular pressure in patients with ocular hypertension and glaucoma., has several other brand drugs in the same treatment category and using the same active ingredient (Latanoprost). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Abbvie |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Latanoprost. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Latanoprost, Iyuzeh's active ingredient. Check the complete list of approved generic manufacturers for Iyuzeh
About Iyuzeh
Iyuzeh is a drug owned by Thea Pharma Inc. It is used for reducing intraocular pressure in patients with ocular hypertension and glaucoma. Iyuzeh uses Latanoprost as an active ingredient. Iyuzeh was launched by Thea in 2022.
Approval Date:
Iyuzeh was approved by FDA for market use on 13 December, 2022.
Active Ingredient:
Iyuzeh uses Latanoprost as the active ingredient. Check out other Drugs and Companies using Latanoprost ingredient
Treatment:
Iyuzeh is used for reducing intraocular pressure in patients with ocular hypertension and glaucoma.
Dosage:
Iyuzeh is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.005% | SOLUTION/DROPS | Prescription | OPHTHALMIC |